Insulin resistance (IR) is a crucial factor in metabolic disorders like non-alcoholic fatty liver disease (NAFLD) and polycystic ovary syndrome (PCOS), ...

Many of the talks led back to the mental health crisis, which has overtaken cancer and obesity to become the biggest global health concern. Industry leaders laid out their visions for alleviating the ...

AstraZeneca is the latest pharma company enlisting the services of Chinese biotechs, signing a deal worth up to $5.2bn with ...

Discover how digital innovation in clinical trial technology—eClinical platforms, remote data capture, and decentralized ...

A team of researchers from Keio University School of Medicine, Kyoto Prefectural University of Medicine, and Teikyo ...

Scientists from the A*STAR Genome Institute of Singapore (A*STAR GIS) have developed a new artificial intelligence (AI)-based ...

AstraZeneca has signed an AI-led research agreement with China's CSPC Pharmaceutical Group worth up to $5.3 billion, which ...

The technology’s potential to transform trials will need to be balanced with the challenge of instilling trust in participants.

Previous exclusion of women in clinical trials has resulted in a data gap ... the need to include sex as a variable in our future studies,” she said. Inspired by AI’s performance, several groups of ...

Recent studies assessed artificial intelligence (AI) assistance tools in their ability to provide quality medical recommendations for patients.

Tempus will use its "Lens" data analytics platform to analyze and restructure genomic data from the the Abrams Research Center.

The American Medical Association has established a new policy that aims to increase transparency and trust in AI tools used in clinical care. The policy was approved during the AMA’s annual meeting ...